12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Redectane 124-Iodine-girentuximab regulatory update

Wilex said it accepted an offer from FDA to participate in an advisory committee meeting to discuss the development and regulatory pathway of kidney cancer diagnostic Redectane. Wilex said FDA made the offer at a meeting with the company to...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >